Yüklüyor......
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
Significant advances in the management of patients with ulcerative colitis (UC) have been made since the introduction of anti-tumor necrosis factor (TNF)-alpha agents, especially for those who fail or do not tolerate conventional therapies. Two drugs, infliximab first, then adalimumab afterward, sho...
Kaydedildi:
| Yayımlandı: | Drug Healthc Patient Saf |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4745853/ https://ncbi.nlm.nih.gov/pubmed/26893582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S62649 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|